In this episode, we dive into the hottest updates in myeloma and amyloidosis at ASH 2024 annual meeting with Dr. Rakesh Popat. Here are the abstracts we discussed:

1. AQUILA Trial in High-Risk SMM

• Overview of the AQUILA trial testing single-agent daratumumab for high-risk smoldering multiple myeloma (HR-SMM) versus active monitoring.
•  Discussion on patient characteristics, primary endpoints, and results showing significant progression-free survival (PFS) benefit with Dara.
•  Insights into modes of progression, adequacy of active surveillance, and post-protocol therapy in control arm.
•  Read the abstract.
•  Read the simultaneous publication at NEJM. 

2. Anito-Cel: New BCMA CAR T Therapy

•  Early data from the iMMagine-1 trial showing strong efficacy and a promising safety profile for Anito-Cel, a novel BCMA CAR T.
•  Discussion of its potential to rival cilta-cel while avoiding neurotoxicity concerns.
•  Read the abstract.

3. CARTITUDE-4 Update

•  Updates on MRD-negativity rates and survival outcomes for cilta-cel in relapsed myeloma, with significant benefits over standard care.
•  Read the abstract.

4. ANDROMEDA OS Data in AL Amyloidosis

•  Long-term data showing an overall survival (OS) benefit of Dara-VCd over VCd in AL amyloidosis.
•  Insights into cardiac responses and crossover impact.
•  Read the abstract.

5. OPTIMUM Trial in Ultra-High-Risk NDMM

• Five-year follow-up of a tailored approach for ultra-high-risk newly diagnosed myeloma patients with continuous therapy incorporating multiple active agents. 
• Subgroup outcomes highlighting both challenges and exceptional results.
•  Read the abstract

6. GMMG-HD7 Trial PFS Update

•  Phase 3 trial results on Isa-VRD vs. VRD induction and risk-adapted tandem ASCT.
•  Discussion on the role of CD38 in maintenance therapy.
•  Read the abstract
•  Read the simultaneous publication at JCO

7. Exciting New Drugs

•  Review of three innovative therapies: inobrodib, a BCMA-CD38 trispecific antibody, and cevostamab, a FcRH5-targeted bispecific antibody.
•  Expert insights into their efficacy and potential to reshape myeloma care.
•  Read the abstract